Skip to contentB
Biogen Inc.
B
BIIBBiogen Inc. Q4 2020 · 10-K
Revenue$2.85B$2.85B−22.3% vs Q4 2019 Net Income$357.90M$357.90M−75.1% vs Q4 2019 EPS Diluted$2.32$2.32−71.3% vs Q4 2019 Gross Profit$2,361,900,000−26.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$367,100,000N/M Free Cash Flowderived-$453,100,000N/M Margins · derivedGross margin82.8%−5.0 pt vs Q4 2019
Operating margin-11.6%−60.0 pt vs Q4 2019
Net margin12.5%−26.7 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 3, 2021 · 34 d after period end